A narrative review synthesizing regulatory frameworks, guidelines, and implementation status of ATMPs in an emerging market; informs policy and institutional strategy rather than clinical practice or mechanistic evidence.
A structured narrative review synthesizing evidence on host-state biomarkers and clinical factors for CLTI cell therapy trial design, proposing a conceptual framework for prognostic stratification rather than reporting new primary efficacy data.
This is a mechanistic lineage-tracing study in genetically modified mice that identifies CAR cells as a source of endosteal osteoblasts and adipocytes, but lacks clinical outcome data, human validation, or therapeutic intervention testing needed to guide practice.